Insightec spins out Lotus Neuro to advance focused ultrasound brain therapies beyond essential tremor
Summary
Insightec announced the spinout of Lotus Neuro in December 2025, establishing an independent company to advance focused ultrasound brain therapies for neurological conditions beyond Insightec's core essential tremor and Parkinson's disease tremor applications. Lotus Neuro will pursue FUS therapeutic indications including Alzheimer's disease, depression, and OCD, where preliminary data suggests focused ultrasound neuromodulation may produce meaningful clinical benefit. The spinout allows both Insightec and Lotus Neuro to focus on their respective programs with dedicated capital structures and leadership teams, rather than competing internally for resources between a commercial business (Insightec Exablate) and early-stage therapeutic R&D (Lotus Neuro).
Why it matters
Insightec spinning out Lotus Neuro is a strategic acknowledgment that Alzheimer's, depression, and OCD FUS programs require different capital, timelines, and risk profiles from a commercially operating essential tremor business. Rather than underfund these programs internally, Insightec creates an independent vehicle that can raise venture capital appropriate to early-stage therapeutic risk while Insightec focuses on commercial expansion of Exablate Neuro.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial